Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (Stages IB and II)

Scandinavian Journal of Gastroenterology

Volumn 31, Issue 5, 1996, Pages 481-489

  Baretton, G B ^a   Vogt, M ^a   Muller C ^a   Diebold, J ^a   Schneiderbanger, K ^a   Schmidt, M ^a   Lohrs U ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chromosome 17; Colorectal carcinoma; DNA cytometry; Immunohistochemistry; In situ hybridization; Interphase cytogenetics; p53; Tumor stages IB and II

Indexed keywords

ARTICLE; CANCER STAGING; CHROMOSOME 17; COLORECTAL CARCINOMA; CYTOGENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0029949185     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609006769     Document Type: Article

References (49)

1. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995;75 Suppl: 154-70.
2. Statistisches Bundesamt. Statistisches Jahrbuch 1993 für die Bundesrepublik Deutschland (German Federal Office for Statistics. Statistical yearbook 1993 for the Federal Republic of Germany). Wiesbaden: Statistisches Bundesamt, 1993.
3. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman MS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322: 352-8.
4. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
5. Wood DA, Robbins GF, Zippin C, Lum D, Stearns M. Staging of cancer of the colon and the rectum. Cancer 1979;43:961-8.
6. UICC. International Union Against Cancer. TNM-atlas: illustrated guide to the TNM/pTNM-classification of malignant tumors. New York: Springer, 1993.
7. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
9. Remvikos Y, Tominaga O, Hammel P, Laurent Puig P, Salmon RJ, Dutrillaux B, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992;66:758-64.
10. Starzynska T, Bromery M. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
11. Hopman AH, van Hooren E, van de Kaa CA, Vooijs PG, Ramaekers FC. Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancers. Mod Pathol 1991;4:503-13.
12. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
13. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
14. Jass JR, Sobin LH. Histological typing of intestinal tumours. World Health Organization. International Classification of Tumours. Berlin: Springer, 1989.
15. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, McDonald S, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
16. Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Löhrs U. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 1994; 54:4472-80.
17. Hopman ANH, Ramaekers FCS, Vooijs GP. Interphase cytogenetics of solid tumours. In: Polak JM, McGee JO, editors. In situ hybridization: principles and practice. Oxford: Oxford University Press, 1989:165-86.
18. Stock C, Ambros IM, Mann G, Gadner H, Amann G, Ambros PF. Detection of 1p36 deletions in paraffin sections of neuroblastoma tissues. Genes Chromosom Cancer 1993;6:1-9.
19. Baretton G, Müller M, Schneiderbanger K, Wirtz A, Wisser J, Arnholdt H, et al. Cytogenetic aberrations in abortions: correlation of conventional karyotyping and interphase cytogenetics on tissue sections and nuclear suspensions. Path Res Pract 1995;191:206 (98).
20. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA-content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
21. Baretton G, Gille J, Oevermann E, Löhrs U. Flow-cytometric analysis of the DNA-content in paraffin-embedded tissue from colorectal carcinomas and its prognostic significance. Virchows Arch [Cell Pathol] 1991; 60:123-31.
22. van den Berg FM, Tigges AJ, Schipper MEI, Den Hartog-Jager FCA, Kroes WGM, Walboomers JMM. Expression of the nuclear oncogene p53 in colon tumours. J Pathol 1989;157: 193-9.
23. Campo E, de la Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, et al. Loss of heterozygosity of p53 gene and p53 gene product in human colorectal carcinomas. Cancer Res 1991;51:4436-42.
24. Purdie CA, O'Gradie J, Piris J, Wyllie AH, Bird CC. P53 expression in colorectal tumors. Am J Pathol 1991;138:807-13.
25. Kawasaki Y, Monden T, Morimoto H, Murotani M, Miyoshi Y, Kobayshi T, et al. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 1992;97: 244-9.
26. Wynford-Thomas D. p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1992;166:329-30.
27. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994;25:435-7.
28. Baas I, Mulder J-WR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
29. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
30. Hamelin R, Laurent Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
31. Steiner MG, Harlow SP, Colombo E, Bauer KD. Chromosomes 8, 12, and 17 copy number in Astler-Coller stage C colon cancer in relation to proliferative activity and DNA ploidy. Cancer Res 1993;53:681-6.
32. Offerhaus GJA, De Feyter EP, Cornelisse CJ, Tersmette KWF, Floyd J, Kern SE, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-9.
33. Meling GI, Lothe RA, Borresen AL, Graue C, Hauge S, Clausen OP, et al. The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables. Br J Cancer 1993;67:93-8.
34. Laurent Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
35. Brodeur GM. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med 1994;330:637-8.
36. Hall JM, Lee MK, Newman B. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9.
37. Makos Wales M, Biel MA, El Deiry W, Nelkin BD, Issa JP, Cavanee WK, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature [Med] 1995;1:570-7.
38. Galandiuk S, Miseljic S, Yang AR, Early M, McCoy MD, Wittliff JL. Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. Arch Surg 1993;128:637-42.
39. Armitage NC, Robins RA, Evans DF, Turner DR, Baldwin RW, Hardcastle JD. The influence of tumor cell DNA abnormalities on survival in colorectal cancer. Br J Surg 1985;72:828-30.
40. Armitage NC, Ballantyne KC, Evans DF, Clarke P, Sheffield J, Hardcastle JD. The influence of tumour cell DNA content on survival in colorectal cancer: a detailed analysis. Br J Cancer 1990;62:852-6.
41. Goh HS, Jass JR, Atkin WS, Cuzick J, Northover JMA. Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariable analysis. Int J Colorect Dis 1987;2:17-21.
42. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reimann HM, Cha SS, Wieand HS, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991;68:879-88.
43. De Angelis P, Stokke T, Smedshammer L, Lothe RA, Meling GI, Rofstad M, et al. p53 expression is associated with a high degree of tumor DNA aneuploidy and incidence of p53 gene mutation, and is localized to the aneuploid component in colorectal carcinomas. Int J Oncol 1993;3:305-12.
44. El-Naggar AK, van Dekken HD, Ensign LG, Pathak S. Interphase cytogenetics in paraffin-embedded sections from renal cortical neoplasms. Correlation with cytogenetic and flow cytometric DNA ploidy analyses. Cancer Genet Cytogenet 1994;73:134-41.
45. Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Nystrom Lehti M, Seruca R, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 1993;53:5853-5.
46. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-61.
47. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
48. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom Lahti M, Pylkkanen L, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-52.
49. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.